Clinical Analysis Of Monotherapy With Gefitinib Or Combined With YH-16 As The Treatment For Patients With Advanced Stage Non-small Lung Cancer

Objectiver:To evaluate the efficacy and the side-effects of gefitinib or gefitinib combined with YH-16 as the treatment in patients with advanced non-small cell lung cancer.Method:The investigation collected 9 non-small cell lung cancer patients who belong to the VIP department of the First Clinical Hospital of Dalian Medical University from May 2006 to December 2009,all patients received gefitinib(AstraZeneca) of 250mg/d, two of them also received YH-16(Yantai Medgenn Co,Ltd)(intravenous infusion),they would discontinued the targeted treatment because of disease progression or other reasons. The patients who received over two cycles of treatment were observed the effect,the side-effects, the clinical symptom and quality of live. All patients were followed up to March 2010,we observed their survival situation.Result:Among 7 patients who take gefitinib alone:CR,PR,SD,PD,DCR were 0case(0%),2cases (28.6%),4cases (57.1%).1case (14.3%),85.7%. Adverse events:skin rash 71.4%(5/7), nausea 71.4%(5/7), diarrhea 57.1% (4/7),dysfunction 14.3%(1/7).The improved situation of the patients 'clinical symptoms and living quality:There are 5 patients who had the clinical symptoms(cough,short of breath,pain,et al),in 5-20 day after treatment,4 patients'clinical symptoms were relifed.1 patient's condition dete-riorated.4 patients'ECOG mark remained as before,2 patients' ECOG mark declined.After treatment,the quality of live of 5 patient was improved. survival situation:all patients were followed up to March 2010,3 patients were survival,4 patients were dead for the reason of disease deterioration. Among 2 patients who take gefitinib combined with YH-16:The two patients'short-term effects were both SD, adverse events were mild skin rash and abdominal distension, clinical symptoms were relifed.1 patient's ECOG mark declined from 4 to 2.The two patients both discontinued the targeted treatment because of economic reasons,so we did not see the Long-term effect.After the treatment,most of the patients' clinical symptoms and living quality were improved.Rash, nausea,diarrhea, hepatic dysfunction (GPT increase) were the most common adverse events, all the adverse events were mild and tolerable to the patients.there was no bone marrow supp-ression, cardiac toxicity and interstitial lung disease in the adverse events.Conclusion:Gefitinib is an effective therapy for patients with advan-ced non-small cell lung cancer with acceptable side effects. It can improve the clinical symptom and quality of live of the NSCLC patients.It is worth popularizing.Gefitinib combined with YH-16 had good short-term effects, improved the clinical symptom and quality of live of the NSCLC patients and it had good tolerance to treat NSCLC.It is feasible to conduct randomized clinical trial to demonstrate the role of the two targeted drug.